Japan Limits Company Contributions To Drug Review Board Members
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare approved a new rule regulating the voting rights of review board members. The rule states that members of the drug review board who received more than ¥5 million in a single year over the past three years will not be allowed to review and vote on applications, and members who received more than ¥500,000 but less than ¥5 million will not be able to vote.The scope of contributions include: contributions to scholarships, compensation such as patient usage fees and contributions to voting members' immediate relatives.Last year, Chugai Pharmaceutical, the Japanese distributor of Tamiflu (oseltamivir), was found contributing money to members of a research team studying the relationship between abnormal behavior and Tamiflu use. The new regulation is an effort to keep MHLW's drug approval procedure fair and transparent. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.